COVID-19 & CancerFreeNCI Sharpless: COVID-19 expected to increase mortality by at least 10,000 deaths from breast and colorectal cancers over 10 years June 19, 2020Vol.46 No.25By Matthew Bin Han Ong
COVID-19 & CancerFreeNCI Sharpless: COVID-19 threatens to reverse long-running trend of decreasing cancer mortality May 15, 2020Vol.46 No.20By Matthew Bin Han Ong
COVID-19 & CancerFreeNCI Sharpless: NCI is fully operational, we have a moral obligation to help in the COVID-19 pandemic response April 14, 2020Vol.46 No.16By Matthew Bin Han Ong
NCI Sharpless addresses three big issues in cancer in 2020:1. NCI grantees are prime targets for foreign influence, 2. Treatment seems to drive drop in lung cancer deaths, 3. RPG paylines to rise from 8% to 10% February 14, 2020Vol.46 No.07By Matthew Bin Han Ong
NCI Sharpless reflects on his time at FDA: “The engine producing new cancer therapies and diagnostics is doing very well” December 06, 2019Vol.45 No.45By Matthew Bin Han Ong
NCI Lowy: NCI needs 15% budget increase to reach FY2021 goal of 15th percentile for paylines September 06, 2019Vol.45 No.33By Matthew Bin Han Ong
NCI Sharpless: Please stay in oncology, don’t stop sending good research ideas to NCI February 15, 2019Vol.45 No.07By Matthew Bin Han Ong
NCI What NCI did with the money: Sharpless boosts funding for RPGs, centers, SPOREs, NCTN, and NCORP June 29, 2018Vol.44 No.26By Matthew Bin Han Ong
NCI Sharpless: NCI should increase funding for RPG pool to maintain success rates for R01s February 16, 2018Vol.44 No.07
NCI Sharpless lists initial priorities for NCI: Big Data, cell therapy, and more trials at the NIH Clinical Center December 01, 2017Vol.43 No.44By Matthew Bin Han Ong
